Reshaping Clot Removal in VTE

THE NEED IS NOW

Venous thromboembolism (VTE) is the third leading cause of cardiovascular death after heart attack and stroke.1 Globally, there are approximately 10 million VTE cases each year, with pulmonary embolism (PE) responsible for the majority of VTE-related deaths.1,2 Mechanical thrombectomy enables physicians to remove thrombus without reliance on lytic drugs and restore blood flow more immediately.

A COMPLETE SOLUTION

Hēlo® Thrombectomy Platform

Venous thromboembolism (VTE) is the third leading cause of cardiovascular death after heart attack and stroke.1 Globally, there are approximately 10 million VTE cases each year, with pulmonary embolism (PE) responsible for the majority of VTE-related deaths.1,2 Mechanical thrombectomy enables physicians to remove thrombus without reliance on lytic drugs and restore blood flow more immediately.

EFFECTIVE CLOT REMOVAL

Large-bore engagement, continuous aspiration, and mechanical clot disruption

STEERABLE NAVIGATION

15F crossing profile, dual-curve control

NEAR-ZERO BLOOD LOSS

Streamlined single-operator blood return system

Learn More

Dive into the details on our product page.

PATIENT TESTIMONIAL

MISSION DRIVEN INVESTORS

E2 and HELO® IN THE NEWS

07 Apr, 2026

E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves

19 Mar, 2026

Endovascular Engineering Announces Dual Late-Breaking Presentations at SIR and SCAI 2026 Highlighting Validation of Blood Return and Comprehensive ENGULF Study Results

03 Nov, 2025

E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference

02 Sep, 2025

E2 (Endovascular Engineering, Inc.) Appoints Justin Farry as Chief Financial Officer to Support Next Phase of Growth

Learn more about Hēlo® Thrombectomy SystemClinical Science

PRODUCT PAGE